Biodexa Reports Enrollment of Initial Patients in Key Phase 3 Serenta Trial for Familial Adenomatous Polyposis (FAP)
Biodexa's Phase 3 Trial Announcement: Biodexa Pharmaceuticals has enrolled the first two patients in its pivotal Phase 3 Serenta trial for eRapa, targeting familial adenomatous polyposis (FAP), a hereditary condition that can lead to colorectal cancer.
Market Opportunity: The company aims to be a first mover in a $7.3 billion addressable market for FAP treatments, as current options are limited to surgical interventions.
Trial Details: The Serenta trial will involve 168 patients and is designed to evaluate the safety and efficacy of eRapa, an oral formulation of rapamycin, as a non-surgical treatment for FAP.
Support and Funding: The trial is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which has significantly contributed to cancer research funding in Texas.
Get Free Real-Time Notifications for Any Stock
Analyst Views on BDRX
About BDRX
About the author
Biodexa Pharmaceuticals Appoints Fiona Sharp as CFO, Shares Rise 3.45%
- Executive Transition: Biodexa Pharmaceuticals has promoted Fiona Sharp to Chief Financial Officer and Company Secretary, effective immediately, aiming to strengthen financial management and enhance operational efficiency within the company.
- Succession Plan: Sharp succeeds Stephen Stamp, who will continue as Chief Executive Officer, ensuring stability and continuity in the company's leadership during this transition.
- Financial Expertise: Having served as Group Financial Controller since December 2019, Sharp brings extensive financial management experience, previously holding the position of Assistant Director of Finance at Hywel Dda University Health Board, which is expected to enhance the company's financial strategy.
- Market Reaction: BDRX shares are currently trading at $2.54, reflecting a 3.45% increase from the previous trading day, indicating positive market sentiment regarding the new CFO's appointment and confidence in the company's future growth prospects.
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
